Pharma-Bio Serv, Inc. (PBSV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 10-31. Amounts in USD.

Revenue Annual

0 7M 14M 21M FY21: 20.1M FY22: 19.4M FY23: 17M FY24: 9.5M FY25: 9M FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 2M 4M 6M FY21: 5.4M FY22: 4.9M FY23: 5.1M FY24: 2.5M FY25: 2.9M FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-4.5M -3M -1.5M 0 1.5M 3M 4.5M FY21: -3.9M FY22: 1.2M FY23: 1.1M FY24: -1.3M FY25: -637.7K FY21 FY22 FY23 FY24 FY25

Net Income Annual

-2.4M -1.6M -800K 0 800K 1.6M 2.4M FY21: -2.1M FY22: 1M FY23: 1.3M FY24: -777.6K FY25: -100.5K FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 6M 12M 18M FY21: 14.8M FY22: 14.5M FY23: 11.9M FY24: 7M FY25: 6.1M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-700K 0 700K 1.4M 2.1M FY21: 804.8K FY22: 592.5K FY23: 1.9M FY24: -566.7K FY25: -214.9K FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-1.4M -700K 0 700K 1.4M 2.1M FY21: 794K FY22: 573.2K FY23: 1.9M FY24: -726.4K FY25: -221.5K FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 8M 16M 24M FY21: 23.2M FY22: 23M FY23: 23M FY24: 23M FY25: 23M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.18 -0.12 -0.06 0.00 0.06 0.12 0.18 Q4 '14: 0.10 Q1 '15: 0.09 Q2 '15: 0.09 Q3 '15: 0.08 Q4 '15: 0.07 Q1 '16: 0.07 Q2 '16: 0.06 Q3 '16: 0.03 Q4 '16: -0.01 Q1 '17: -0.04 Q2 '17: -0.06 Q3 '17: -0.06 Q4 '17: -0.06 Q1 '18: -0.16 Q2 '18: -0.15 Q3 '18: -0.11 Q4 '24: -0.08 Q1 '25: -0.06 Q2 '25: -0.05 Q3 '25: -0.06 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.